CS
KBIO

Credit Suisse’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Credit Suisse’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,833
Closed -$33K – 4910
2014
Q2 		$33K Buy
1,833
+176
+11% +$3.01K ﹤0.01% 4613
2014
Q1 		$36K Sell
1,657
-506
-23% -$14.7K ﹤0.01% 4596
2013
Q4 		$76K Buy
+2,163
New +$72.5K ﹤0.01% 4501

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.45B AUM 5.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Credit Suisse's KBIO Position: Q3 2014 in Review

Credit Suisse sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q3 2014, closing a stake of 1,833 shares — an estimated $33K sold.

Credit Suisse first reported a position in KBIO in Q4 2013 and held it in 3 quarters. The position peaked at $76K in Q4 2013. 35 funds tracked by Wall St. Rank hold KBIO as of Q3 2014.

  • Credit Suisse reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q3 2014 after selling out during the quarter.
  • Credit Suisse sold 1,833 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q3 2014, an estimated $33K.
  • Credit Suisse first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q4 2013 and held it in 3 quarters.
  • Credit Suisse's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $76K in Q4 2013.
  • 35 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q3 2014.

Based on Credit Suisse's 13F filing for Q3 2014, filed 14 Nov 2014.